JP6117780B2 - 薬物およびアルコールの乱用の治療に有用なオルビノール誘導体およびテビノール誘導体 - Google Patents

薬物およびアルコールの乱用の治療に有用なオルビノール誘導体およびテビノール誘導体 Download PDF

Info

Publication number
JP6117780B2
JP6117780B2 JP2014519623A JP2014519623A JP6117780B2 JP 6117780 B2 JP6117780 B2 JP 6117780B2 JP 2014519623 A JP2014519623 A JP 2014519623A JP 2014519623 A JP2014519623 A JP 2014519623A JP 6117780 B2 JP6117780 B2 JP 6117780B2
Authority
JP
Japan
Prior art keywords
methyl
methoxy
cyclopropylmethyl
dihydro
epoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2014519623A
Other languages
English (en)
Japanese (ja)
Other versions
JP2014522854A5 (cg-RX-API-DMAC10.html
JP2014522854A (ja
Inventor
ルイス、ジョン
ハズバンズ，スティーブン
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Bath
Original Assignee
University of Bath
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Bath filed Critical University of Bath
Publication of JP2014522854A publication Critical patent/JP2014522854A/ja
Publication of JP2014522854A5 publication Critical patent/JP2014522854A5/ja
Application granted granted Critical
Publication of JP6117780B2 publication Critical patent/JP6117780B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C07D489/12—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14 the bridge containing only two carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/4748—Quinolines; Isoquinolines forming part of bridged ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/485—Morphinan derivatives, e.g. morphine, codeine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/32—Alcohol-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/30—Drugs for disorders of the nervous system for treating abuse or dependence
    • A61P25/36—Opioid-abuse
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D489/00—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula:
    • C07D489/09—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems
    • C07D489/10—Heterocyclic compounds containing 4aH-8, 9 c- Iminoethano-phenanthro [4, 5-b, c, d] furan ring systems, e.g. derivatives of [4, 5-epoxy]-morphinan of the formula: containing 4aH-8, 9 c-Iminoethano- phenanthro [4, 5-b, c, d] furan ring systems condensed with carbocyclic rings or ring systems with a bridge between positions 6 and 14
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/08—Bridged systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Addiction (AREA)
  • Epidemiology (AREA)
  • Psychiatry (AREA)
  • Emergency Medicine (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
JP2014519623A 2011-07-08 2012-07-05 薬物およびアルコールの乱用の治療に有用なオルビノール誘導体およびテビノール誘導体 Active JP6117780B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1111775.1 2011-07-08
GBGB1111775.1A GB201111775D0 (en) 2011-07-08 2011-07-08 Compounds and uses thereof
PCT/GB2012/051575 WO2013007986A1 (en) 2011-07-08 2012-07-05 Orvinol and thevinol derivatives useful in the treatment of drug and alcohol abuse

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2015135460A Division JP6117862B2 (ja) 2011-07-08 2015-07-06 薬物およびアルコールの乱用の治療に有用なオルビノール誘導体およびテビノール誘導体

Publications (3)

Publication Number Publication Date
JP2014522854A JP2014522854A (ja) 2014-09-08
JP2014522854A5 JP2014522854A5 (cg-RX-API-DMAC10.html) 2015-08-27
JP6117780B2 true JP6117780B2 (ja) 2017-04-19

Family

ID=44544490

Family Applications (2)

Application Number Title Priority Date Filing Date
JP2014519623A Active JP6117780B2 (ja) 2011-07-08 2012-07-05 薬物およびアルコールの乱用の治療に有用なオルビノール誘導体およびテビノール誘導体
JP2015135460A Active JP6117862B2 (ja) 2011-07-08 2015-07-06 薬物およびアルコールの乱用の治療に有用なオルビノール誘導体およびテビノール誘導体

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2015135460A Active JP6117862B2 (ja) 2011-07-08 2015-07-06 薬物およびアルコールの乱用の治療に有用なオルビノール誘導体およびテビノール誘導体

Country Status (15)

Country Link
US (5) US9051334B2 (cg-RX-API-DMAC10.html)
EP (1) EP2729469B1 (cg-RX-API-DMAC10.html)
JP (2) JP6117780B2 (cg-RX-API-DMAC10.html)
CA (1) CA2841169C (cg-RX-API-DMAC10.html)
CY (1) CY1117674T1 (cg-RX-API-DMAC10.html)
DK (1) DK2729469T3 (cg-RX-API-DMAC10.html)
ES (1) ES2572508T3 (cg-RX-API-DMAC10.html)
GB (1) GB201111775D0 (cg-RX-API-DMAC10.html)
HR (1) HRP20160389T1 (cg-RX-API-DMAC10.html)
HU (1) HUE028785T2 (cg-RX-API-DMAC10.html)
PL (1) PL2729469T3 (cg-RX-API-DMAC10.html)
RS (1) RS54830B1 (cg-RX-API-DMAC10.html)
SI (1) SI2729469T1 (cg-RX-API-DMAC10.html)
SM (1) SMT201600154B (cg-RX-API-DMAC10.html)
WO (1) WO2013007986A1 (cg-RX-API-DMAC10.html)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201111775D0 (en) 2011-07-08 2011-08-24 Univ Bath Compounds and uses thereof
WO2013050748A2 (en) 2011-10-03 2013-04-11 Johnson Matthey Plc An improved method of preparing buprenorphine
EP3087078B1 (en) * 2013-12-26 2019-05-15 Purdue Pharma LP 7-beta-alkyl analogs of orvinols
TW201607923A (zh) 2014-07-15 2016-03-01 歌林達有限公司 被取代之氮螺環（４．５）癸烷衍生物
GB201716830D0 (en) 2017-10-13 2017-11-29 Cambrex Charles City Inc New Process
CN110117288A (zh) * 2018-02-07 2019-08-13 复旦大学 7β-甲基-奈培酮衍生物及其制备方法和用途
CN114195798B (zh) * 2021-12-31 2023-07-28 复旦大学 7α-甲基稠环吗啡类衍生物及其制备方法和用途

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1136214A (en) 1965-06-15 1968-12-11 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB937214A (en) 1961-06-02 1963-09-18 J F Macfarlan & Company Ltd Oripavine derivatives
US3474101A (en) 1960-09-05 1969-10-21 Reckitt & Sons Ltd Thebaine and oripavine derivatives
GB925723A (en) 1960-09-05 1963-05-08 J F Macfarlan & Company Ltd Novel thebaine derivatives
GB902659A (en) 1961-02-02 1962-08-09 J F Macfarlan & Company Ltd A process for the production of a derivative of thebaine
NL289751A (cg-RX-API-DMAC10.html) 1962-03-02
DE1493696A1 (de) 1965-02-17 1969-12-18 Hoechst Ag Verfahren zur Herstellung klarfluessiger,leicht mit Wasser verduennbarer Fettsaeurekondensationsprodukte
WO2004078178A1 (en) 2003-03-03 2004-09-16 Markus Heilig Buprenorphine compounds for treatment of alcohol dependence and excessive alcohol use
GB201111775D0 (en) * 2011-07-08 2011-08-24 Univ Bath Compounds and uses thereof
JP6314571B2 (ja) * 2013-12-16 2018-04-25 ヤマハ株式会社 反力発生装置

Also Published As

Publication number Publication date
US20170044173A1 (en) 2017-02-16
EP2729469B1 (en) 2016-03-30
DK2729469T3 (en) 2016-07-18
RS54830B1 (sr) 2016-10-31
SMT201600154B (it) 2016-08-31
CA2841169A1 (en) 2013-01-17
ES2572508T3 (es) 2016-05-31
US10030031B2 (en) 2018-07-24
CA2841169C (en) 2019-08-27
US9259422B2 (en) 2016-02-16
US9480684B2 (en) 2016-11-01
JP2015172089A (ja) 2015-10-01
US20140213603A1 (en) 2014-07-31
WO2013007986A1 (en) 2013-01-17
SI2729469T1 (sl) 2016-07-29
JP6117862B2 (ja) 2017-04-19
HUE028785T2 (en) 2017-01-30
US9051334B2 (en) 2015-06-09
US20150202200A1 (en) 2015-07-23
CY1117674T1 (el) 2017-05-17
US9890170B2 (en) 2018-02-13
EP2729469A1 (en) 2014-05-14
PL2729469T3 (pl) 2016-09-30
US20160136151A1 (en) 2016-05-19
GB201111775D0 (en) 2011-08-24
HK1198031A1 (zh) 2015-03-06
US20180030062A1 (en) 2018-02-01
HRP20160389T1 (hr) 2016-07-01
JP2014522854A (ja) 2014-09-08

Similar Documents

Publication Publication Date Title
JP6117862B2 (ja) 薬物およびアルコールの乱用の治療に有用なオルビノール誘導体およびテビノール誘導体
DK2418211T3 (en) DEUTERATED MORPHINAN COMPOUNDS
JP5525524B2 (ja) ブプレノルフィン類似体
EP2941431B1 (en) Substituted morphinans and the use thereof
JP2015516410A (ja) オピオイド受容体モジュレーターとしてのベンゾモルファン化合物
WO2014170704A1 (en) Deuterated morphine derivatives
EP3077398B1 (en) Novel opioid compounds and their uses
HUE025569T2 (en) Morphine Compounds
HK1198031B (en) Orvinol and thevinol derivatives useful in the treatment of drug and alcohol abuse
Maksay et al. Synthesis of (nor) tropeine (di) esters and allosteric modulation of glycine receptor binding
Schutz et al. Synthesis and pharmacological evaluation of 18, 19-dehydrobuprenorphine
Zhang et al. Synthesis of dopamine transporter selective 3-diarylmethoxymethyl-8-arylalkyl-8-azabicyclo [3.2. 1] octane derivatives
AU2015258262B2 (en) Morphinan compounds
HK1154856B (en) Morphinan compounds

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20150706

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20150706

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20160210

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160216

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20160516

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160719

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A132

Effective date: 20160816

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20161115

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20170221

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20170323

R150 Certificate of patent or registration of utility model

Ref document number: 6117780

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250